Presentation: Wednesday, September 5th 11:50am – 12:20pm
Presenter: Joan Foster
Implications of Choosing the Right Cell Engineering Technology on Biotherapeutic Development
Are increasing productivity and maximizing data relevance mutually exclusive during biotherapeutic development when working in an environment of limited resources? Not necessarily if you can work with the manufacturing host cell early in development to produce sufficient quantities of candidates for extensive characterization and thus progression of the most promising candidates in a cost-efficient manner. One often overlooked aspect of success is employing the right means of cell engineering, such as MaxCyte’s high-performance, cell engineering technology, to drive rapid, scalable production of even the most difficult-to-express proteins in the manufacturing cell background while maintaining flexibility in downstream culture processes. This presentation discusses how the high performance and flexibility of MaxCyte’s cell engineering technology positively impacts therapeutic efficacy, laboratory productivity, and fast-tracks biotherapeutic development.Conference Site
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter